eccogene glp-1 Elecoglipron Shows Positive Results in Phase 1b Trial in China | posted on the topic AstraZeneca licenses Eccogene's oral GLP-1

Our Loop Workforce Health Index data: 37.2% of urban professionals already show abnormal glucose metabolism

Feel more like yourself again

Dariush Mozaffarian, added, Each year, suboptimal diets and food insecurity cause more than 500,000 deaths and cost the U.S

So before we move quickly to external GLP-1 support, a more important question is: Are we activating endogenous pathways effectively

The GLP-1 Revolution: The Companies Dominating One of Pharma's Fastest-Growing Markets The global GLP-1 market has transformed from a niche diabetes segment into one of the most valuable therapeutic categories in pharmaceutical history